Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. ETF
  3. RVMD
RVMD logo

RVMD

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewTechnicalNews
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

RVMD News

Revolution Medicines Q1 2026 Earnings Call Insights

3d agoseekingalpha

Revolution (RVMD) Q1 2026 Earnings Transcript

3d agoNASDAQ.COM

Revolution Medicines Reports Clinical Trial Results for Daraxonrasib

3d agoNewsfilter

Analysis of XBI ETF Trading Dynamics

4d agoNASDAQ.COM

Revolution Medicines, Inc. Gains Attention for Huge Upside Potential

May 02 2026Yahoo Finance

FDA Approves Revolution Medicines' Cancer Therapy for Expanded Access

May 01 2026seekingalpha

Erasca's Cancer Drug Trial Data Triggers Stock Plunge

Apr 28 2026seekingalpha

Erasca's Cancer Therapy Trial Reports Treatment-Related Death

Apr 28 2026stocktwits

Revolution Medicines Stock Soars 250% Despite No Revenue

Apr 27 2026Fool

Revolution Medicines' Promising Drug Sparks Investor Excitement

Apr 27 2026NASDAQ.COM

Revolution Medicines Updates Clinical Data on Daraxonrasib for Pancreatic Cancer

Apr 22 2026NASDAQ.COM

Revolution Medicines Releases Clinical Data on Daraxonrasib

Apr 21 2026Newsfilter

Revolution Medicines Presents Phase 3 Trial Results for Daraxonrasib

Apr 21 2026Newsfilter

Revolution Medicines Releases Updated Clinical Data for Zoldonrasib

Apr 19 2026Newsfilter

Revolution Medicines Closes Upsized Offering of 12.1 Million Shares

Apr 17 2026Newsfilter

Revolution Medicines Raises Approximately $1.5 Billion in Public Offering

Apr 15 2026seekingalpha